AtriCure Q3 Loss Narrows 90.9%, Revenue Beats by 2.1%
AtriCure reported a third-quarter 2025 adjusted loss of $0.01 per share, narrowing the shortfall by 90.9% versus consensus, while revenues of $134.3 million exceeded forecasts by 2.1%. The company holds a Zacks Rank #2 and forecasts 109.1% earnings growth for fiscal 2026 against a 15.8% industry baseline.
1. Q3 2025 Earnings
AtriCure’s third-quarter 2025 results showed an adjusted loss of $0.01 per share, a 90.9% improvement over analyst projections, while revenue reached $134.3 million, topping estimates by 2.1%. This marks the fourth consecutive quarter of earnings surprises for the device maker.
2. Zacks Rank and Growth Projections
The company currently holds a Zacks Rank #2 (Buy) and projects a stunning 109.1% increase in earnings for fiscal 2026 compared to a 15.8% rise across its industry. Such a forecast underscores expectations for rapid margin expansion and sales growth.
3. Strategic Outlook and Market Position
With back-to-back beats on both top- and bottom-line figures, AtriCure’s outlook hinges on scaling device sales and improving operational leverage. Sustained execution on new product launches and efficiency initiatives will be critical to meeting its lofty growth targets.